Abstract: Embodiments of the present disclosure are directed to coated glass articles which reduce glass particle formation caused by glass to glass contact in pharmaceutical glass filling lines.

Abstract: According to embodiments, a coated pharmaceutical container may include a pharmaceutical container comprising an interior surface and an exterior surface, wherein the pharmaceutical container may include a glass composition that has Class HGA1 hydrolytic resistance when tested according to the ISO 720 testing standard. The coated pharmaceutical container may further include a coating bonded to at least a portion of the exterior surface but not on any portion of the interior surface. The coating may have a coefficient of friction less than or equal to 0.7, and the coated pharmaceutical container may be thermally stable after heating at a temperature of at least 260° C. for a time period of 30 minutes.

Abstract: According to embodiments, a method of making a coated pharmaceutical container, may include: forming a glass tube; forming the glass tube into a pharmaceutical container comprising an interior surface and an exterior surface; and applying a coating to the exterior surface. The coating has a coefficient of friction less than or equal to 0.7 relative to a second pharmaceutical container when tested in a vial-on-vial testing jig under a normal load of 30 N. The coated pharmaceutical container may be thermally stable after depyrogenation at a temperature of at least 260° C. for 30 minutes in air.

Abstract: Coated pharmaceutical packages are disclosed. The coated pharmaceutical packages may Include a glass body formed from borosilicate glass that meets Type 1 criteria according to USP <660> or alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A low-friction coating comprising a polymer may be positioned on a portion of the exterior surface. A coefficient of friction of an abraded area of the portion of the exterior surface with the low-friction coating may be less than 0.7 after exposure to a temperature of 260° C. for 30 minutes and abrasion under a load of at least 10 N and does not have observable damage. A retained strength of the coated glass article in horizontal compression does not decrease by more than 20% after the temperature exposure and the abrasion.

Abstract: Coated pharmaceutical packages may comprise a glass body formed from a borosilicate glass composition having a Type 1 chemical durability according to USP 660, the glass body having an interior surface and an exterior surface and a wall extending therebetween. A low-friction thermally stable coating having a thickness of ?1 ?m may be positioned on at least a portion of the exterior surface. The low-friction coating may comprise a silane. The portion of the exterior surface of the coated pharmaceutical package may have a coefficient of friction that is at least 20% less than an uncoated pharmaceutical package formed from the same borosilicate glass composition.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include a glass body having a Class HGA1 hydrolytic resistance when tested according to the ISO 720:1985 testing standard. The glass body may have an interior surface and an exterior surface. The interior surface of the glass body does not comprise a boron-rich layer when the glass body is in an as-formed condition. A heat-tolerant coating may be bonded to at least a portion of the exterior surface of the glass body. The heat-tolerant coating may have a coefficient of friction of less than about 0.7 and is thermally stable at a temperature of at least 250° C. for 30 minutes.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include a glass body having a Class HGA1 hydrolytic resistance when tested according to the ISO 720:1985 testing standard. The glass body may have an interior surface and an exterior surface. The interior surface of the glass body does not comprise a boron-rich layer when the glass body is in an as-formed condition. A heat-tolerant coating may be bonded to at least a portion of the exterior surface of the glass body. The heat-tolerant coating may have a coefficient of friction of less than about 0.7 and is thermally stable at a temperature of at least 250° C. for 30 minutes.

Abstract: Glass articles with coatings are disclosed herein. According to embodiments, a glass article may include a glass body comprising glass and having a first surface and a second surface opposite the first surface, wherein the first surface is an exterior surface of the glass body. A coating disposed on at least a portion of the exterior surface of the glass body. The coated glass article may have an effective throughput rate greater than or equal to 1.10×RT, wherein RT is the effective throughput rate of an uncoated glass article in units of parts per minute (ppm).

Abstract: Glass articles with coatings are disclosed herein. According to embodiments, a glass article may include a glass body comprising glass and having a first surface and a second surface opposite the first surface, wherein the first surface is an exterior surface of the glass body. A coating disposed on at least a portion of the exterior surface of the glass body. The coated glass article may have an effective throughput rate greater than or equal to 1.10×RT, wherein RT is the effective throughput rate of an uncoated glass article in units of parts per minute (ppm).

Abstract: One or more aspects of the disclosure pertain to an article including a film disposed on a glass substrate, which may be strengthened, where the interface between the film and the glass substrate is modified, such that the article retains its average flexural strength, and the film retains key functional properties for its application. Some key functional properties of the film include optical, electrical and/or mechanical properties. The bridging of a crack from one of the film or the glass substrate into the other of the film or the glass substrate can be prevented by inserting a crack mitigating layer between the glass substrate and the film.

Abstract: Coated pharmaceutical packages are disclosed. The coated pharmaceutical packages may include a glass body formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A low-friction coating may be positioned on at least a portion of the first surface of the glass body the low-friction coating may include a polymer and a coupling agent disposed between the polymer and the first surface of the glass body. A coefficient of friction of the portion of the coated pharmaceutical package with the low-friction coating is at least 20% less than a coefficient of friction of a surface of an uncoated pharmaceutical package formed from the same glass composition.

Abstract: One or more aspects of the disclosure pertain to an article including a film disposed on a glass substrate, which may be strengthened, where the interface between the film and the glass substrate is modified, such that the article retains its average flexural strength, and the film retains key functional properties for its application. Some key functional properties of the film include optical, electrical and/or mechanical properties. The bridging of a crack from one of the film or the glass substrate into the other of the film or the glass substrate can be prevented by inserting a crack mitigating layer between the glass substrate and the film.

Abstract: Coated pharmaceutical packages may comprise a glass body formed from a borosilicate glass composition having a Type 1 chemical durability according to USP 660, the glass body having an interior surface and an exterior surface and a wall extending therebetween. A low-friction thermally stable coating having a thickness of ?1 ?m may be positioned on at least a portion of the exterior surface. The low-friction coating may comprise a silane. The portion of the exterior surface of the coated pharmaceutical package may have a coefficient of friction that is at least 20% less than an uncoated pharmaceutical package formed from the same borosilicate glass composition.

Abstract: Coated pharmaceutical packages are disclosed. The coated pharmaceutical packages may include a glass body comprising a first surface and a second surface opposite the first surface. The glass body may be a glass container formed from a borosilicate glass composition and the first surface is an exterior surface of the glass container. A low-friction coating may be positioned on at least a portion of the first surface of the glass body. In embodiments, the low-friction coating may be a fluoropolymer.

Abstract: Coated glass pharmaceutical packages are disclosed. According to embodiments, a coated glass pharmaceutical package may include a glass container formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP <660> or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A low-friction coating may be bonded to the exterior surface of the glass container. The low-friction coating may include a polymer. The exterior surface of the glass container with the low-friction coating may have a coefficient of friction of less than or equal to 0.7. The coated glass pharmaceutical package may be thermally stable after depyrogenation in air at a temperature of at least about 260° C. for 30 minutes.

Abstract: One or more aspects of the disclosure pertain to an article including a film disposed on a glass substrate, which may be strengthened, where the interface between the film and the glass substrate is modified, such that the article retains its average flexural strength, and the film retains key functional properties for its application. Some key functional properties of the film include optical, electrical and/or mechanical properties. The bridging of a crack from one of the film or the glass substrate into the other of the film or the glass substrate can be prevented by inserting a crack mitigating layer between the glass substrate and the film.

Abstract: Embodiments of the present disclosure are directed to coated glass articles which reduce glass particle formation caused by glass to glass contact in pharmaceutical glass filling lines.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include an aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to ISO 720-1985 testing standard. The glass containers may also have a compressive stress layer with a depth of layer of greater than 25 ?m. A surface compressive stress of the glass containers may be greater than or equal to 350 MPa. The delamination resistant glass pharmaceutical containers may be ion exchange strengthened and the ion exchange strengthening may include treating the delamination resistant glass pharmaceutical container in a molten salt bath for a time less than or equal to 5 hours at a temperature less than or equal to 450° C.

Abstract: According to embodiments, a method of making a coated pharmaceutical container, may include: forming a glass tube; forming the glass tube into a pharmaceutical container comprising an interior surface and an exterior surface; and applying a coating to the exterior surface. The coating may have a coefficient of friction less than or equal to 0.7 relative to a second pharmaceutical container when tested in a vial-on-vial testing jig under a normal load of 30 N. The coated pharmaceutical container may be thermally stable after depyrogenation at a temperature of at least 260° C. for 30 minutes in air.

Abstract: Embodiments of the present disclosure are directed to coated glass articles which reduce glass particle formation caused by glass to glass contact in pharmaceutical glass filling lines.